ANTITHROMBIN AND THROMBOLYTIC EFFECTS OF A NEW ANTITHROMBIN AGENT - ANGIOSCOPIC AND ANGIOGRAPHIC COMPARISON WITH HEPARIN OR BATROXOBIN

被引：11

作者：

TOMARU, T

NAKAMURA, E

MIWA, AY

FUJIMORI, Y

OMATA, M

OKADA, R

UCHIDA, Y

机构：

[1] The Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Tokyo

[2] Cardiology Division, Juntendo University, Tokyo

来源：

JOURNAL OF INTERVENTIONAL CARDIOLOGY | 1994年 / 7卷 / 05期

关键词：

D O I：

10.1111/j.1540-8183.1994.tb00478.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The antithrombotic effect of three different types of antithrombotic agents (antithrombin:argatroban, heparin, defibrinogenating agent:batroxobin) were evaluated in canine coronary and iliac arteries. An occlusive thrombus formation (heparin 250 U/kg, argatroban 0.5 mg/kg, batroxobin 0.5 U/kg) and the effect of thrombus size reduction was evaluated. On the contralateral side of the iliac artery, the preventive effect of these agents on thrombus formation was evaluated after balloon injury. In the iliac artery, angioscopic percent area obstruction by the thrombus before and 60 minutes after treatment reduced from 69% to 32% in the argatroban group, and from 64% to 51% in the batroxobin group (P < 0.0001 and P < 0.05, respectively). No significant change was observed in the heparin group. Angiography demonstrated the same trend. The percent area stenosis with thrombus at 60 minutes following balloon injury was 0.75% in the argatroban group, 18.9% in the heparin group (P < 0.05 vs argatroban), and 12.9% in the batroxobin group. Thrombus size at the treated site was smaller than that at the control site in all three groups (P < 0.05 vs control). In the coronary artery, angioscopic percent area obstruction by the thrombus before and 60 minutes after treatment reduced from 84% to 53% in the argatroban group, and from 86% to 68% in the batroxobin group (P < 0.001 and P < 0.05, respectively). No significant change was observed in the heparin group. Angiography also demonstrated the same trend. The activated partial thromboplastin time (APTT) was prolonged to 189% of the control value with argatroban and to 1253% of the value with heparin (P < 0.001). Fibrinogen was markedly reduced with batroxobin. These results showed that both the antithrombin agent and the defibrinogenating agent have a preventive effect on thrombus formation and the effect on thrombus size reduction, without marked prolongation of the APTT.

引用

页码：409 / 419

页数：11

共 23 条

[1] Eisenberg PR, Sherman LA, Jaffe AS, Paradoxical elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis, JACC, 10, pp. 527-529, (1987)
[2] Walford GD, Midei MM, Aversano TR, Et al., Heparin after PICA, Circulation, 84, pp. 11-592, (1991)
[3] Gold HK, Leinbach RC, Yasuda T, Et al., Acute coronary reocclusion after thrombolysis with recombinant human tissue type plasminogen activator: Prevention by a maintenance infusion, Circulation, 73, pp. 347-352, (1986)
[4] Schaer DH, Ross AM, Wasserman AG, Reinfarction, recurrent angina, and reocclusion after thrombolytic therapy, Circulation, 76, pp. 57-62, (1987)
[5] Bang BU, Wilhelm OG, Glayman MD, After coronary thrombolysis and reperfusion, what next, JACC, 14, pp. 837-849, (1989)
[6] Gold HK, Coller BS, Yasuda T, Et al., Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue type plasminogen activator and monoclonal antiplatelet GP IIb/IIa antibody in a canine preparation, Circulation, 77, pp. 670-677, (1988)
[7] Fitzgerald DJ, Wright F, Fitzgerald GA, Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue type plasminogen activator in vivo, Circ Res, 65, pp. 83-94, (1989)
[8] Mirshahi M., Soria J, Soria C, Et al., Evaluation of the inhibition by heparin and hirudin of coagulation activation during r‐tPA‐induced thrombolysis, Blood, 74, pp. 1025-1030, (1989)
[9] Fitzgerald DJ, Fitzgerald GA, Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue‐type plasminogen activator, Proc Natl Acad Sci, USA, 86, pp. 7585-7589, (1989)
[10] Heras M, Chesebro JH, Penny WI, Et al., Effects of thrombin inhibition on the development of acute platelet‐thrombus deposition during angioplasty in pigs, Circulation, 79, pp. 657-665, (1989)

← 1 2 3 →